A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT06619522
Phase
PHASE2
Status
Withdrawn

Conditions

  • Myelofibrosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ruxolitinib — DRUG
    Given orally
  • INCB57643 — DRUG
    Given orally

Study Details

To assess INCB05643 + ruxolitinib JAKi-naive patients with myelofibrosis

Key Dates

Start date
Sep 11, 2024
Status verified
May 2025
Primary completion
May 9, 2025
Completion
May 9, 2025

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: INCB+ R

Primary Outcome Measure

Safety and Adverse Events (AEs). Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) [ Time Frame: Through study completion; an average of 1 year ]

Related Studies